Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Up 22.9% in April

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 43,400 shares, an increase of 22.9% from the March 31st total of 35,300 shares. Based on an average daily volume of 65,900 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.3% of the shares of the company are short sold.

Aileron Therapeutics Trading Down 1.6 %

Shares of NASDAQ ALRN opened at $4.92 on Tuesday. The firm has a market cap of $83.49 million, a price-to-earnings ratio of -1.46 and a beta of 2.22. The stock has a fifty day simple moving average of $5.42 and a two-hundred day simple moving average of $3.77. Aileron Therapeutics has a 1-year low of $1.01 and a 1-year high of $7.42.

Aileron Therapeutics (NASDAQ:ALRN) last posted its quarterly earnings results on Monday, April 15th. The company reported ($1.54) earnings per share for the quarter. Analysts forecast that Aileron Therapeutics will post -0.62 EPS for the current year.

Wall Street Analyst Weigh In

Separately, LADENBURG THALM/SH SH lifted their price objective on shares of Aileron Therapeutics from $9.00 to $19.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th.

Institutional Trading of Aileron Therapeutics

A hedge fund recently bought a new stake in Aileron Therapeutics stock. Texas Capital Bank Wealth Management Services Inc purchased a new stake in Aileron Therapeutics, Inc. (NASDAQ:ALRN) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 15,773 shares of the company’s stock, valued at approximately $48,000. Texas Capital Bank Wealth Management Services Inc owned 0.32% of Aileron Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 90.89% of the company’s stock.

About Aileron Therapeutics

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.